Valcyte is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS). Valcyte is indicated for the prevention of CMV disease in CMV-negative adults and children (aged from birth to 18 years) who have received a solid organ transplant from a CMV-positive donor.
Cymevene is indicated in adults and adolescents ≥ 12 years of age for the: - treatment of cytomegalovirus (CMV) disease in immunocompromised patients; - prevention of CMV disease using pre-emptive therapy in patients with drug-induced immunosuppression (for example following organ transplantation or cancer chemotherapy). Cymevene is also indicated from birth for the: - prevention of CMV disease using universal prophylaxis in patients with drug-induced immunosuppression (for example following organ transplantation or cancer chemotherapy). Consideration should be given to official guidance on the appropriate use of antiviral agents.
Fintpla (fenfluramine) oral solution has been approved by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older